The trifunctional antibody catumaxomab amplifies and shapes tumor-specific immunity when applied to gastric cancer patients in the adjuvant setting

Human Vaccines and Immunotherapeutics

Volumn 9, Issue 12, 2013, Pages 2533-2542

  Atanackovic, Djordje ^a   Reinhard, Henrike ^a   Meyer, Sabrina ^a   Spöck, Stefanie ^a   Grob, Tobias ^a   Luetkens, Tim ^a   Yousef, Sara ^a   Cao, Yanran ^a   Hildebrandt, York ^a   Templin, Julia ^a   Bartels, Katrin ^a   Lajmi, Nesrine ^a   Stoiber, Heribert ^b   Kröger, Nicolaus ^a   Atz, Judith ^c   Seimetz, Diane ^c   Izbicki, Jakob R ^a   Bokemeyer, Carsten ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b Social Medicine Medical University IBK   (Austria)

^c Fresenius Biotech   (Germany)

Author keywords

Adjuvant immunotherapy; Catumaxomab; EpCAM; Gastric cancer; T cells; Tumor immunology

Indexed keywords

CANCER TESTIS ANTIGEN; CATUMAXOMAB; CD69 ANTIGEN; CHEMOKINE RECEPTOR CXCR3; EPITHELIAL CELL ADHESION MOLECULE; PLATINUM COMPLEX; TUMOR ANTIGEN;

ANTIBODY RESPONSE; ARTICLE; CANCER ADJUVANT THERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; DRUG DOSE ESCALATION; EFFECTOR CELL; GASTRECTOMY; HUMAN; HUMAN CELL; HUMAN TISSUE; HUMORAL IMMUNITY; MULTICENTER STUDY (TOPIC); PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 2 CLINICAL TRIAL (TOPIC); STOMACH CANCER; T LYMPHOCYTE ACTIVATION; TH1 CELL; TUMOR IMMUNITY;

ADJUVANT IMMUNOTHERAPY; CATUMAXOMAB; EPCAM; GASTRIC CANCER; T CELLS; TUMOR IMMUNOLOGY;

ANTIBODIES, BISPECIFIC; EUROPE; HUMANS; IMMUNOLOGIC FACTORS; STOMACH NEOPLASMS; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 84893134949     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.26065     Document Type: Article

References (50)

1. Crew KD, Neugut AI. Epidemiolog (Pubitemid 43329250)
2. Maehara Y, Hasuda S, Koga T., Tokunaga E, Kakeji Y, Sugimachi K. Postoperative outcome and sites of recurrence in patients following curative resection of gastric cancer. Br J Surg 2000; 87: 353-7; PMID: 10718807; http://dx.doi.org/10.1046/j.1365-2168.2000.01358.x (Pubitemid 30156364)
3. Cunningham D, Allum WH, Stenning S.P., Thompson JN, Van de Velde CJ, Nicolson M, Scarffe J.H., Lofts FJ, Falk SJ, Iveson TJ, et al.; MAGIC Trial Participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11-20; PMID: 16822992; http://dx.doi.org/10.1056/NEJMoa055531
4. Moriguchi S, Maehara Y, Korenaga D., Sugimachi K, Nose Y. Risk factors which predict pattern of recurrence after curative surgery for patients with advanced gastric cancer. Surg Oncol 1992; 1: 341-6; PMID: 1341269; http://dx.doi.org/10.1016/0960-7404(92)90034-I
5. Roviello F, Marrelli D, de Manzoni G, Morgagni P, Di Leo A, Saragoni L, De Stefano A; Italian Research Group for Gastric Cancer. Prospective study of peritoneal recurrence after curative surgery for gastric cancer. Br J Surg 2003; 90: 1113-9; PMID: 12945079; http://dx.doi.org/10.1002/bjs.4164 (Pubitemid 37152170)
6. Wu CW, Lo SS, Shen K.H., Hsieh MC, Chen JH, Chiang JH, Lin H.J., Li AF, Lui WY. Incidence and factors associated with recurrence patterns after intended curative surgery for gastric cancer. World J Surg 2003; 27: 153-8; PMID: 12616428 (Pubitemid 36920163)
7. Yoo CH, Noh SH, Shin D.W., Choi SH, Min JS. Recurrence following curative resection for gastric carcinoma. Br J Surg 2000; 87: 236-42; PMID: 10671934; http://dx.doi.org/10.1046/j.1365-2168.2000.01360.x (Pubitemid 30088655)
8. Okines AF, Cunningham D. Multimodality treatment for localized gastro-oesophageal cancer. Ann Oncol 2010; 21(Suppl 7): vii286-93; PMID: 20943630; http://dx.doi.org/10.1093/annonc/mdq282
9. Setälä LP, Kosma VM, Marin S, Lipponen PK, Eskelinen MJ, Syrjänen KJ, Alhava EM. Prognostic factors in gastric cancer: the value of vascular invasion, mitotic rate and lymphoplasmacytic infiltration. Br J Cancer 1996; 74: 766-72; PMID: 8795580; http://dx.doi.org/10.1038/bjc.1996.434 (Pubitemid 26300769)
10. Kamoi D, Ishii H, Takahashi H., Aoyama T, Toriyama T, Tanaka M., Kawamura Y, Kawashima K, Yoshikawa D., Amano T, et al. Sirolimus- vs. paclitaxel-eluting stent to coronary intervention in dialysis patients. Int J Cardiol 2013; 165: 533-6; PMID: 22000423; http://dx.doi.org/10.1016/j.ijcard.2011.09.078
11. Lee HE, Chae SW, Lee Y.J., Kim MA, Lee HS, Lee BL, Kim WH. Prognostic implications of type and density of tumour-infiltrating lymphocytes in gastric cancer. Br J Cancer 2008; 99: 1704-11; PMID: 18941457; http://dx.doi.org/10. 1038/sj.bjc.6604738
12. Gronau S, Schmitt M, Reinhardt P., Wiesneth M, Riechelmann H. [T-cells activated with a trifunctional bi-specific antibody in head and neck cancer]. Laryngorhinootologie 2005; 84: 822-8; PMID: 16358189; http://dx.doi.org/10.1055/ s-2005-861448 (Pubitemid 41756025)
13. Riesenberg R, Buchner A, Pohla H, Lindhofer H. Lysis of prostate carcinoma cells by trifunctional bispecific antibodies (alpha EpCAM x alpha CD3). J Histochem Cytochem 2001; 49: 911-7; PMID: 11410615; http://dx.doi.org/ 10.1177/002215540104900711 (Pubitemid 32565984)
14. Gronau SS, Schmitt M, Thess B., Reinhardt P, Wiesneth M, Schmitt A., Riechelmann H. Trifunctional bispecific antibody-induced tumor cell lysis of squamous cell carcinomas of the upper aerodigestive tract. Head Neck 2005; 27: 376-82; PMID: 15818557; http://dx.doi.org/10.1002/hed.20170 (Pubitemid 40593891)
15. Zeidler R, Reisbach G, Wollenberg B., Lang S, Chaubal S, Schmitt B., Lindhofer H. Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing. J Immunol 1999; 163: 1246-52; PMID: 10415020 (Pubitemid 29352740)
16. Ruf P, Lindhofer H. Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody. Blood 2001; 98: 2526-34; PMID: 11588051; http://dx.doi.org/10.1182/blood.V98.8.2526
17. Schmitt M, Schmitt A, Reinhardt P., Thess B, Manfras B, Lindhofer H., Riechelmann H, Wiesneth M, Gronau S. Opsonization with a trifunctional bispecific (alphaCD3 x alphaEpCAM) antibody results in efficient lysis in vitro and in vivo of EpCAM positive tumor cells by cytotoxic T lymphocytes. Int J Oncol 2004; 25: 841-8; PMID: 15375531
18. Zeidler R, Mysliwietz J, Csánady M, Walz A., Ziegler I, Schmitt B, Wollenberg B., Lindhofer H. The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells. Br J Cancer 2000; 83: 261-6; PMID: 10901380 (Pubitemid 30411727)
19. Heiss MM, Murawa P, Koralewski P., Kutarska E, Kolesnik OO, Ivanchenko V.V., Dudnichenko AS, Aleknaviciene B, Razbadauskas A, Gore M., et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial. Int J Cancer 2010; 127: 2209-21; PMID: 20473913; http://dx.doi.org/10.1002/ijc.25423
20. Heiss MM, Ströhlein MA, Jäger M, Kimmig R., Burges A, Schoberth A, Jauch K.W., Schildberg FW, Lindhofer H. Immunotherapy of malignant ascites with trifunctional antibodies. Int J Cancer 2005; 117: 435-43; PMID: 15906359; http://dx.doi.org/10.1002/ijc.21165 (Pubitemid 41429567)
21. Burges A, Wimberger P, Kümper C, Gorbounova V., Sommer H, Schmalfeldt B, Pfisterer J., Lichinitser M, Makhson A, Moiseyenko V., et al. Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: A phase I/II study. Clin Cancer Res 2007; 13: 3899-905; PMID: 17606723; http://dx.doi.org/10.1158/1078- 0432.CCR-06-2769 (Pubitemid 47037597)
22. Jäger M., Schoberth A, Ruf P., Hess J, Hennig M, Schmalfeldt B., Wimberger P, Ströhlein M, Theissen B., Heiss MM, et al. Immunomonitoring results of a phase II/III study of malignant ascites patients treated with the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3). Cancer Res 2012; 72: 24-32; PMID: 22044753; http://dx.doi.org/10.1158/0008-5472.CAN-11-2235
23. Kodera Y, Yamamura Y, Shimizu Y., Torii A, Hirai T, Yasui K., Morimoto T, Kato T. Peritoneal washing cytology: prognostic value of positive findings in patients with gastric carcinoma undergoing a potentially curative resection. J Surg Oncol 1999; 72: 60-4, discussion 64-5; PMID: 10518099; http://dx.doi.org/ 10.1002/(SICI)1096-9098(199910)72:2<60::AID-JSO3>3.0.CO;2-1 (Pubitemid 29504122)
24. Kodera Y, Nakanishi H, Ito S., Yamamura Y, Fujiwara M, Koike M., Hibi K, Ito K, Tatematsu M., Nakao A. Prognostic significance of intraperitoneal cancer cells in gastric carcinoma: detection of cytokeratin 20 mRNA in peritoneal washes, in addition to detection of carcinoembryonic antigen. Gastric Cancer 2005; 8: 142-8; PMID: 16086116; http://dx.doi.org/10.1007/s10120-005-0318-7 (Pubitemid 41176092)
25. Kodera Y, Nakanishi H, Ito S., Mochizuki Y, Ohashi N, Yamamura Y., Fujiwara M, Koike M, Tatematsu M., Nakao A. Prognostic significance of intraperi-toneal cancer cells in gastric carcinoma: analysis of real time reverse transcriptase-polymerase chain reaction after 5 years of followup. J Am Coll Surg 2006; 202: 231-6; PMID: 16427547; http://dx.doi.org/10.1016/j. jamcollsurg.2005.09.008 (Pubitemid 43112481)
26. Shi C, Yang B, Chen Q., Yang J, Fan N. Retrospective analysis of adjuvant intraperitoneal chemotherapy effect prognosis of resectable gastric cancer. Oncology 2011; 80: 289-95; PMID: 21778768; http://dx.doi.org/10.1159/000329075
27. Went P, Vasei M, Bubendorf L., Terracciano L, Tornillo L, Riede U., Kononen J, Simon R, Sauter G., Baeuerle PA. Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers. Br J Cancer 2006; 94: 128-35; PMID: 16404366; http://dx.doi.org/10. 1038/sj.bjc.6602924 (Pubitemid 43088552)
28. Kondo T, Ito F, Nakazawa H., Horita S, Osaka Y, Toma H. High expression of chemokine gene as a favorable prognostic factor in renal cell carcinoma. J Urol 2004; 171: 2171-5; PMID: 15126779; http://dx.doi.org/10.1097/01.ju. 0000127726.25609.87 (Pubitemid 38625428)
29. Bonecchi R, Bianchi G, Bordignon P.P., D'Ambrosio D, Lang R, Borsatti A., Sozzani S, Allavena P, Gray P.A., Mantovani A., et al. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J Exp Med 1998; 187: 129-34; PMID: 9419219; http://dx.doi.org/10.1084/jem.187.1.129 (Pubitemid 28044828)
30. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006; 6: 295-307; PMID: 16557261; http://dx.doi.org/10.1038/nri1806
31. Berntsen A, Brimnes MK, thor Straten P, Svane IM. Increase of circulating CD4+CD25highFoxp3+ regulatory T cells in patients with metastatic renal cell carcinoma during treatment with dendritic cell vaccination and low-dose interleukin-2. J Immunother 2010; 33: 425-34; PMID: 20386464; http://dx.doi.org/10.1097/CJI.0b013e3181cd870f
32. Yagi H, Nomura T, Nakamura K., Yamazaki S, Kitawaki T, Hori S., Maeda M, Onodera M, Uchiyama T., Fujii S, et al. Crucial role of FOXP3 in the development and function of human CD25+CD4+ regulatory T cells. Int Immunol 2004; 16: 1643-56; PMID: 15466453; http://dx.doi.org/10.1093/intimm/dxh165 (Pubitemid 39480783)
33. Salgado FJ, Lojo J, Fernández-Alonso CM, Viñuela J, Cordero OJ, Nogueira M. Interleukin-dependent modulation of HLA-DR expression on CD4and CD8 activated T cells. Immunol Cell Biol 2002; 80: 138-47; PMID: 11940114; http://dx.doi.org/10.1046/j.1440-1711.2002.01055.x (Pubitemid 34298086)
34. Rosenberg SA, Sherry RM, Morton K.E., Scharfman WJ, Yang JC, Topalian SL, Royal R.E., Kammula U., Restifo NP, Hughes MS, et al. Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J Immunol 2005; 175: 6169-76; PMID: 16237114 (Pubitemid 41508105)
35. Speiser DE, Liénard D, Rufer N., Rubio-Godoy V, Rimoldi D, Lejeune F., Krieg AM, Cerottini JC, Romero P. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest 2005; 115: 739-46; PMID: 15696196 (Pubitemid 40322250)
36. Appay V, Jandus C, Voelter V., Reynard S, Coupland SE, Rimoldi D, Lienard D., Guillaume P, Krieg AM, Cerottini J.C., et al. New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumor site. J Immunol 2006; 177: 1670-8; PMID: 16849476 (Pubitemid 44092503)
37. Rezvani K, Yong AS, Mielke S, Jafarpour B., Savani BN, Le RQ, Eniafe R, Musse L., Boss C, Kurlander R, et al. Repeated PR1 and WT1 peptide vaccination in Montanide-adjuvant fails to induce sustained high-avidity, epitope-specific CD8+ T cells in myeloid malignancies. Haematologica 2011; 96: 432-40; PMID: 21134985; http://dx.doi.org/10.3324/haematol.2010.031674
38. Aoyama T, Yoshikawa T, Hayashi T., Kuwabara H, Mikayama Y, Ogata T., Cho H, Tsuburaya A, Rino Y., Masuda M. [S-1/krestin immunochemotherapy for patients with advanced gastric cancer]. Gan To Kagaku Ryoho 2011; 38: 1921-3; PMID: 22202239
39. Hirschhaeuser F, Walenta S, Mueller-Klieser W. Efficacy of catumaxomab in tumor spheroid killing is mediated by its trifunctional mode of action. Cancer Immunol Immunother 2010; 59: 1675-84; PMID: 20652245; http://dx.doi.org/10.1007/ s00262-010-0894-1
40. Dettmar K, Seitz-Merwald I, Lindemann C., Schroeder P, Seimetz D, Atz J. Transient lymphocyte decrease due to adhesion and migration following catumaxomab (anti-EpCAM x anti-CD3) treatment in vivo. Clin Transl Oncol 2012; 14: 376-81; PMID: 22551544; http://dx.doi.org/10.1007/s12094-012-0811-5
41. Nishimura T, Nakui M, Sato M., Iwakabe K, Kitamura H, Sekimoto M, Ohta A., Koda T, Nishimura S. The critical role of Th1-dominant immunity in tumor immunology. Cancer Chemother Pharmacol 2000; 46(Suppl): S52-61; PMID: 10950149; http://dx.doi.org/10.1007/PL00014051
42. Berghuis D, Santos SJ, Baelde H.J., Taminiau AH, Egeler RM, Schilham MW, Hogendoorn P.C., Lankester AC. Pro-inflammatory chemokine-chemo-kine receptor interactions within the Ewing sarcoma microenvironment determine CD8(+) T-lymphocyte infiltration and affect tumour progression. J Pathol 2011; 223: 347-57; PMID: 21171080; http://dx.doi.org/10.1002/path.2819
43. Chu Y, Yang X, Xu W., Wang Y, Guo Q, Xiong S. In situ expression of IFN-gamma-inducible T cell alpha chemoattractant in breast cancer mounts an enhanced specific anti-tumor immunity which leads to tumor regression. Cancer Immunol Immunother 2007; 56: 1539-49; PMID: 17659370; http://dx.doi.org/10.1007/ s00262-007-0296-1 (Pubitemid 47094383)
44. Hong M, Puaux AL, Huang C, Loumagne L., Tow C, Mackay C, Kato M., Prévost-Blondel A, Avril MF, Nardin A, et al. Chemotherapy induces intratumoral expression of chemokines in cutaneous melanoma, favoring T-cell infiltration and tumor control. Cancer Res 2011; 71: 6997-7009; PMID: 21948969; http://dx.doi.org/10.1158/0008-5472.CAN-11-1466
45. Musha H, Ohtani H, Mizoi T., Kinouchi M, Nakayama T, Shiiba K., Miyagawa K, Nagura H, Yoshie O., Sasaki I. Selective infiltration of CCR5(+)CXCR3(+) T lymphocytes in human colorectal carcinoma. Int J Cancer 2005; 116: 949-56; PMID: 15856455; http://dx.doi.org/10.1002/ijc.21135 (Pubitemid 41209203)
46. Pan J, Burdick MD, Belperio J.A., Xue YY, Gerard C, Sharma S, Dubinett S.M., Strieter RM. CXCR3/CXCR3 ligand biological axis impairs RENCA tumor growth by a mechanism of immunoangiosta-sis. J Immunol 2006; 176: 1456-64; PMID: 16424173 (Pubitemid 43134288)
47. Pertl U, Luster AD, Varki N.M., Homann D., Gaedicke G, Reisfeld RA, Lode HN. IFN-gamma-inducible protein-10 is essential for the generation of a protective tumor-specific CD8 T cell response induced by single-chain IL-12 gene therapy. J Immunol 2001; 166: 6944-51; PMID: 11359856 (Pubitemid 32467242)
48. Mullins IM, Slingluff CL, Lee J.K., Garbee CF, Shu J, Anderson SG, Mayer M.E., Knaus WA, Mullins DW. CXC chemokine receptor 3 expression by activated CD8+ T cells is associated with survival in melanoma patients with stage III disease. Cancer Res 2004; 64: 7697-701; PMID: 15520172; http://dx.doi.org/10. 1158/0008-5472.CAN-04-2059 (Pubitemid 39446899)
49. Ziegler A, Heidenreich R, Braumüller H, Wolburg H., Weidemann S, Mocikat R, Röcken M. EpCAM, a human tumor-associated antigen promotes Th2 development and tumor immune evasion. Blood 2009; 113: 3494-502; PMID: 19188665; http://dx.doi.org/10.1182/blood-2008-08-175109
50. Atanackovic D, Matsuo M, Ritter E., Mazzara G, Ritter G, Jäger E, Knuth A., Old LJ, Gnjatic S. Monitoring CD4+ T cell responses against viral and tumor antigens using T cells as novel target APC. J Immunol Methods 2003; 278: 57-66; PMID: 12957396; http://dx.doi.org/10.1016/S0022-1759(03)00209-6 (Pubitemid 37281192)